In a study by Liang et al. (2015) that was conducted in the Chinese population, other oncogene mutations found in conjunction with PIK3CA mutations in NSCLC patients included KRAS E2 (11 cases), KRAS E3 (1 case), BRAF (2 cases), EGFR E18 (4 cases), EGFR E20 (5 cases), EGFR E21 (28 cases), and EGFR E19 deletions (37 cases) [26]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.